The Outlook for the CMO Industry


The outlook for the contract manufacturing industry is being shaped by several significant trends. The well-financed pipeline makes the near term outlook favorable, but much depends on the number of new approvals for small and mid-size companies. Injectables CMOs should get better pricing thanks to tight capacity. Mergers and acquisitions will consolidate the industry and the hunger for acquisitions will benefit CMOs with specialty capabilities. CMOs will pursue new business models, including proprietary products, to fuel profit growth.

For more information on the outlook for the CMO industry, download my slides here.

Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.

More posts by Jim Miller